X4 pharmaceuticals, inc (ASNS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-

-

-

-

-

-33,285

0

0

0

-

-

-

-

Net loss

0

-

-

-

0

-

-

-

-

-

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,401

2,050

1,674

1,181

893

759

336

411

438

492

0

0

0

Depreciation and amortization expense

119

103

97

96

97

103

0

26

49

71

0

0

0

Non-cash lease expense

608

569

0

0

0

-

-

-

-

-

-

-

-

Accretion of debt discount

661

695

656

462

278

152

-1,338

-1,161

-757

157

0

0

0

Non-cash rent expense

-

-

-

-

-

-

-

-

-

-

0

0

0

Loss on extinguishment of debt

0

-

-

-

0

-

-

-

-

-

-

-

-

Change in fair value of preferred stock warrant liability

-183

105

3,511

3,466

3,183

3,487

0

0

0

-

-

-

-

Change in fair value of derivative liability

0

-

0

0

0

-

0

0

-565

-

0

0

0

Other

0

-

-

-

0

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

0

-

-

-

0

-

-

-

-

-

-

-

-

Grant and incentive receivables

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepaid expenses, other current assets and research and development incentive receivable

165

-109

62

198

486

-279

-75

-2,600

-2,524

-402

0

0

0

Accounts payable

-4,884

-2,752

-2,033

210

3,202

1,307

-3,302

-1,211

-3,071

-1,169

0

0

0

Accrued expenses

1,564

160

-220

-61

-763

1,549

520

428

505

1,409

0

0

0

Lease liabilities

-762

-753

0

0

0

-

-

-

-

-

-

-

-

Unearned income

-

-

-

-

-

-

-

-

-

-

0

0

0

Net cash used in operating activities

-51,832

-48,055

-45,548

-39,497

-30,988

-25,420

0

0

0

-

-

-

-

Cash flows from investing activities:
Cash, cash equivalents and restricted cash acquired in connection with the Merger

0

-

0

0

0

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Acquisition of property, equipment and intangible assets

729

174

0

0

0

-

-

-

-

378

0

0

0

Net cash provided by investing activities

271

27,232

0

0

0

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from exercise of stock options and warrants

775

792

0

0

0

-

-

-

-

-

-

-

-

Proceeds from borrowings under loan and security agreements, net of issuance costs

0

-

0

0

0

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of Series B convertible preferred stock, net of issuance costs

-

-

-

-

-

-

-

-

-

27,413

0

0

0

Repurchase of Series Seed convertible preferred stock

-

-

-

-

-

1,126

0

0

0

-

-

-

-

Repayments of borrowings under loan and security agreement

-

-

-

-

-

6,380

-250

-165

-82

0

0

0

0

Payments of issuance costs of convertible promissory notes

-

-

-

-

-

-

-

-

-

-

0

0

0

Payments of issuance costs of convertible preferred stock

-

-

-

-

-

-

-

-

0

-

-

-

-

Net cash provided by financing activities

145,532

140,661

85,405

95,814

8,643

6,870

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-263

-250

0

0

0

-

-

-

-

0

0

0

0

Net (decrease) increase in cash, cash equivalents and restricted cash

93,708

119,588

66,802

82,711

4,040

-18,550

-33,404

-31,800

3,071

11,733

0

0

0

Supplemental disclosure of cash flow information
Cash paid for interest

-

-

-

-

-

-

-

-

0

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Issuance costs not yet paid

0

-

-

-

0

-

-

-

-

-

-

-

-

Conversion of convertible preferred stock into common stock

0

-

0

0

0

-

-

-

-

-

-

-

-

Conversion of redeemable common stock into common stock

0

734

0

0

0

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

0

Derivative liability in connection with issuance of convertible promissory notes

-

-

-

-

-

-

-

-

-

-

0

0

0

Conversion of convertible preferred stock warrants into common stock warrants

0

-

0

0

0

-

-

-

-

-

-

-

-

Fair value of net assets acquired in the Merger

-26,406

19,952

0

0

0

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

0

0

0